|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From INSERM U364, Facultè de Mèdecine, Nice
Cedex 02, France.
Fractalkine displays features that distinguishes it from the other
chemokines. In particular, besides its chemoattractant action it
promotes, under physiologic flow, the rapid capture and the firm
adhesion of a subset of leukocytes or intervenes in the
neuron/microglia interaction. This study verified that indeed the human
monocytic MonoMac6 cell line adheres to fibronectin-coated filters in
response to soluble fractalkine (s-FKN). s-FKN stimulates, with
distinct time courses, extracellular signal-related kinases (ERK1 and
ERK2) and stress-activated protein kinases (SAPK1/JNK1 and SAPK2/p38).
Both p60 Src and p72 Syk were activated under s-FKN stimulation
with a rapid kinetic profile compatible with a downstream regulation on
the mitogen-activated protein kinase (MAPK) congeners. The
use of specific tyrosine kinase inhibitors revealed that the ERK
pathway is strictly controlled by Syk, whereas c-Src up-regulated the
downstream SAPK2/p38. In contrast, the SAPK1/JNK1 pathway was not
regulated by any of these nonreceptor tyrosine kinases. The
s-FKN-mediated increased adherence of MonoMac6 cells was partially
inhibited by SB202190, a broad SAPKs inhibitor, PD98059, an MEK
inhibitor, LY294002, a phosphatidyl inositol 3-kinase inhibitor, and a
pertussis toxin-sensitive G protein. These data highlight that the
integration of a complex array of signal transduction pathways is
necessary to complete the full s-FNK-dependent adherence of human
monocytic cells to fibronectin.
(Blood. 2001;97:2031-2037) Chemokines are small secreted proteins that
stimulate the directional migration of leukocytes and mediate
inflammation.1 This superfamily of chemotactic peptides
falls into at least 4 subfamilies principally based on the relative
position of highly conserved cysteine residues in their amino acid
sequences.1,2 Fractalkine is so far the only member of the
Recently, Imai et al have identified and characterized a high-affinity
receptor for fractalkine,8,9 CX3CR1, corresponding to a
classical heptahelical chemokine receptor. This receptor was shown to
mediate both the adhesive and migration functions of fractalkine.
Chemokine receptors identified to date on leukocytes all present a
7-transmembrane G protein-linked structure.10,11 They have
been shown to transduce signals that lead to cytoskeletal reorganization, integrin activation, and other functions required to
increase adhesion and migration of the cells. These effects are
frequently, but not exclusively, mediated through pertussis toxin-sensitive G protein-coupled pathways. Nevertheless, it has been
demonstrated that the association of chemokine receptor to different G
proteins depends on the receptor and the cell line studied.12
Fractalkine displays distinctive biologic activities compared to the
other members of the chemokine family. Under soluble form, this unique
CX3C chemokine was first reported to exert, in vitro, a chemotactic
effect on monocytes, natural killer (NK) cells, and T lymphocytes and
to induce cellular adhesion.3,4,8 However reports
suggested that s-FKN behaves through its receptor CX3CR1, as an
adhesion molecule, able to promote under physiologic flow, the firm
adhesion of a subset of leukocytes. This adhesive function is not
inhibited by pertussis toxin and is integrin
independent.5,13 However, it has recently been
demonstrated that s-FKN can induce adhesion by up-regulating integrin
avidity in a pertussis toxin-sensitive manner.14
To date, information on the cellular signaling triggered by
chemokine is scarce. Chemokines have been shown to trigger biochemical events such as increased intracellular cyclic adenosine monophosphate (cAMP) level,15 phospholipase activation,16
increased tyrosine phosphorylation particularly with the activation of
FAK and ZAP-70,17 stimulation of 2 phosphoinositide-3
kinase (PI3-kinase) isoforms (p85/p110 and C2 In this study, we present evidence that SAPKs, ERKs, and PI3K pathways
have to act in conjunction for the mediation of s-FKN-dependent adhesion of MonoMac6 cells to fibronectin.
Cell culture
Products
Cell stimulation and lysis MonoMac6 cells (106 cells/mL) were starved 16 hours in RPMI 1640 medium and harvested by centrifugation for 5 minutes at 1000g before being resuspended in RPMI at a concentration of 2 × 107 cells/mL. Cells (5 × 106) were treated at 37°C with or without the effectors for the indicated times and lysed 30 minutes at 4°C in a buffer containing 150 mM NaCl, 0.8 mM MgCl2, 5 mM EGTA, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride (PMSF), 15 µg/mL leupeptin, 1 µM pepstatine, and 1 mM Na3VO4 and 50 mM Hepes at pH 7.5. The crude lysates were centrifuged at 18 000g for 10 minutes at 4°C, the supernatants (lysates) were removed, and the protein concentration was assayed using the Bradford method (Biorad, Hercules, CA).Immune-complex kinase assays ERKs and SAPK2/p38 MAPK activities. Cell lysates (100 µg) were boiled after addition of 9 × Laemmli sample buffer prior to being resolved on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto Immobilon-P membranes (Millipore, Bedford, MA) as detailed previously.23 The immunoblots were incubated overnight at 4°C with rabbit polyclonal antiactive ERKs antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) or antiactive p38 antibodies (Promega, Madison, WI). After 3 washes with buffer, 10 mM Tris at pH 7.4, 150 mM NaCl, 1% NP-40, the antibody binding was detected using horseradish peroxidase (HRP)-conjugated goat antirabbit (GAR) antibodies (Dako, Botany, Australia) with the enhanced chemiluminescence (ECL) system with autoradiography hyperfilms MP. The amount of ERKs and SAPK2/p38 was evaluated on each lane after stripping for 30 minutes at 50°C in 67 mM Tris at pH 6.7, 2% SDS, 100 mM 2-mercato-ethanol, by Western blotting using anti ERK2 or SAPK2/p38 antibodies (Santa Cruz Biotechnology) and revealed by chemiluminescence using the ECL kit (Amersham, Arlington Heights, IL) and hyperfilms MP (Amersham). SAPK1/JNK1 activity.
Cell lysates were precleared with rabbit nonimmune serum prebound to
protein A-Sepharose (Pharmacia-LKB Biotechnologies, Uppsala, Sweden) and JNK1 kinase was immunoprecipitated from precleared lysates by incubation at 4°C for 16 hours with 1 µg polyclonal anti-JNK1 antibodies (Santa Cruz Biotechnology) bound to protein A-Sepharose. Immunopellets were washed twice with lysis buffer and
twice with MAP kinase buffer (30 mM NaCl, 0.1% NP-40, 10% glycerol,
200 µM Na3VO4, 30 mM Hepes at pH 7.5) before
being resuspended in 50 µL MAP kinase buffer containing 30 mM
Mg-acetate in the presence of 0.5 mg/mL GST-ATF2, which was used as
exogenous substrate. The kinase assay was initiated by addition of 25 µM adenosine triphosphate (ATP) and 20 µCi/mL
Src kinase activity.
Precleared lysates were incubated at 4°C for 4 hours with 2 µg
polyclonal anti- c-Src antibodies (Argëne Biosof, Varilhes, France) followed by the addition of protein A/G Sepharose (Santa Cruz
Biotechnology), and then incubated for 1 additional hour at 4°C. The
immunopellets were washed twice with lysis buffer, followed by 2 washes
with the tyrosine kinase buffer (10 mM MnCl2, 20 mM Hepes
at pH 7.5). Samples were then resuspended in 50 µL tyrosine kinase
buffer supplemented with 1 mM DTT and 0.1 mg/mL acid-denatured enolase,
which was used as an exogenous substrate. The kinase assay was started
by addition of 3.75 µM ATP and 20 µCi/mL Syk phosphorylation. The Syk kinases were immunoprecipitated from precleared lysates by incubation at 4°C for 3 hours with polyclonal anti-Syk antibodies (Santa Cruz Biotechnology) bound to protein A-Sepharose. Immunopellets were washed twice with lysis buffer, twice with lysis buffer in the presence of 0.25% sodium deoxycholate, and resuspended in 50 µL of 3 × Laemmli sample buffer. Proteins resolved by SDS-PAGE were electrophoretically transferred onto Immobilon-P membrane and tyrosine phosphorylated Syk kinases were detected using 4G10 monoclonal antiphosphotyrosine antibodies (Upstate Biotechnology, Lake Placid, NY). The total amount of immunoprecipitated Syk was evaluated on each lane, after stripping as described above and reprobed with monoclonal anti-Syk antibodies (Santa Cruz Biotechnology) and revealed by chemiluminescence using the ECL kit and hyperfilms MP. PI kinase assays Cleared whole lysates from untreated or s-FKN-stimulated MonoMac6 cells were precipitated with an antiphosphotyrosine monoclonal antibody (Upstate Biotechnology) for 2 hours at 4°C, then protein A-Sepharose beads were added for 1 hour. Immunopellets were treated and subjected to PI kinase assay in the absence or in the presence of either 0.2% Nonidet-P40 or 200 µM adenosine to discriminate between PI3K and PI4K, as previously described.23 Phosphorylated reaction products were extracted by methanol-chloroform and then separated by thin layer chromatography onto silica gel plates (Whatman 60A LK6D). The spots corresponding to the phosphorylated products were visualized by autoradiography.Cell adhesion assays The response of MonoMac6 cells to s-FKN was evaluated by using 24-well migration chambers and polyethylene terephtalate (PET) inserts with 8 µm pores filters (Becton Dickinson, San Jose, CA) coated with 6.5 µg/mL fibronectin (Sigma, St Louis, MO) on both sides. MonoMac6 cells, incubated for 16 hours with [3H]-methyl thymidine (ICN, 2.5 µCi/mL) were placed, in presence or in absence of 60 nM s-FKN, in the upper well (106 cells/100 µL) and RPMI 1640 medium was added in the lower well. Plates were incubated for 3 hours at 37°C in 5% CO2 atmosphere. At the end of the migration assays, fibronectin-coated filters were collected and washed twice in phosphate-buffered saline (PBS) buffer, and the adhesion was evaluated by the measure of the amount of [3H]-methyl thymidine-labeled cells by scintillation spectroscopy.
s-FKN stimulates ERKs and SAPKs activities in human MonoMac6 cells following distinct time courses To study the effects of s-FKN on ERK activities, MonoMac6 cells were treated with s-FKN (60 nM) for various periods of time before being lysed. The activation status of ERK1 and ERK2 was then evaluated by measuring the extent of p42/p44 ERKs phosphorylation with appropriate antibodies. As shown in Figure 1A, s-FKN induced a rapid increase in the level of ERK1 and ERK2 phosphorylation starting at 20 minutes before declining to the basal level by 1 hour.
To further characterize the different signaling pathways triggered in response to s-FKN, we investigated the level of activation of the 2 SAPKs, namely JNK1 and p38. JNK1 activity was assayed in JNK1 immunoprecipitates from lysates of s-FKN-treated MonoMac6 cells, by assaying their ability to phosphorylate GST-ATF2 as substrate. As shown in Figure 1B, s-FKN stimulated JNK1 activity with a kinetic profile markedly delayed compared to the time course observed for ERKs, being detectable only by 2 hours and lasting for up to 5 hours. Similarly, s-FKN stimulated p38 activity with a lag period of 3 hours and persisting for up to 5 hours. Syk- and Src-like protein tyrosine kinases are involved in s-FKN-induced MAPKs activation in MonoMac6 cells We examined the possible involvement of protein tyrosine kinases, often described as implicated in signal transduction from G protein-coupled receptors (GPCRs).24 MonoMac6 cells were preincubated in the presence of either PP2, a potent inhibitor of the Src kinase family,25 or piceatannol, a specific inhibitor of the Syk tyrosine kinase family26 before being exposed to s-FKN.The data presented in Figure 2A show that
these 2 tyrosine kinase inhibitors were without effect on JNK1
activation in response to s-FKN. Instead, s-FKN-induced ERK1
and ERK2 activation was abrogated by piceatannol, with no effect of PP2
suggesting that Syk, but not Src, controlled the s-FKN-mediated
activation of both types of ERKs (Figure 2B).
The inhibitory profile of the 2 tyrosine kinases inhibitors on p38 activation (Figure 2C) mirrored that observed with ERKs, because only PP2 was partially efficient, revealing a specific involvement of Src-like kinases, but not Syk, in the control of s-FKN-induced p38 activation. s-FKN induces Syk phosphorylation and activates c-Src in MonoMac6 cells On the basis of the above data suggesting a possible involvement of Src and Syk in the respective control of p38 and ERKs, we sought to verify whether Src and Syk activities were indeed activated in response to s-FKN. To this end, Src activity present in anti-c-Src immunoprecipitates from lysates of cells exposed to s-FKN was tested. Figure 3A shows that c-Src kinase was sharply activated, peaking at 1 to 2 minutes before declining to the basal level by 5 minutes and rebonding in a biphasic manner by 15 minutes. Syk was immunoprecipitated from s-FKN-treated MonoMac6 cells and pellets were examined for their phosphotyrosine profile. Stimulation of MonoMac6 cells by s-FKN also induced a rapid increase in the level of Syk tyrosine phosphorylation appearing within 1 to 2 minutes (Figure 3B).
s-FKN-induced ERKs, JNK1, and p38 pathways display distinctive sensitivities to cholera and pertussis toxins Chemokine receptors have long been known to be coupled with G proteins sensitive to bacterial toxins.27 To better delineate the involvement of Go/i and Gs proteins in the differential control of ERKs, JNK1, and p38, MonoMac6 cells were pretreated for 4 hours, with pertussis toxin, an inhibitor of Go/i proteins, or cholera toxin, an activator of Gs proteins.Figure 4, panels A and B, show that
s-FKN-mediated ERK1, ERK2, and p38 activation was abrogated by a
previous treatment of MonoMac6 cells with either cholera or pertussis
toxin, suggesting that those pathways did require an upstream
coordinated activation of both Gs and Go/i proteins.
Conversely, JNK1 activity remained unaffected when the cells were treated either for 16 hours by 100 ng/mL pertussis toxin (data not shown) or for 4 hours by 250 ng/mL pertussis toxin or 10 µg/mL cholera toxin (Figure 4C), indicating that neither Gs nor Go/i proteins are involved in the control of JNK1 activation in response to s-FKN. s-FKN stimulates PI kinase activity in MonoMac6 cells Because of the importance of phosphorylation of inositide phospholipids in the activation of several kinases and cytoskeleton remodeling, we sought to determine whether PI kinase was activated in response to s-FNK. Antiphosphotyrosine immunoprecipitates from lysates of s-FKN-treated MonoMac6 cells were tested for their ability to phosphorylate PI. As shown in Figure 5, s-FKN rapidly stimulates a lipid kinase activity detectable within 5 minutes (upper panel), which was virtually abrogated by a pretreatment of the cells with LY294002, a specific inhibitor of the PI3-kinase.28 To define more precisely the nature of the PI kinase activity, we took advantage of the fact that PI3-kinase has been shown to be strongly inhibited by NP-40 detergent and insensitive to the presence of adenosine, a pattern that was symmetrical to that exhibited by PI4K.29 The data presented in Figure 5, lower panel, indicate that the s-FKN-induced lipid-kinase displays all the features of a PI3K. We verified that in our system, PI3K inhibition was without effect on any of the 3 MAPK cascades (data not shown).
s-FKN-induced MonoMac6 cells adhesion to fibronectin is dependent on ERKs, SAPKs, and PI3K pathway activation Chemokine receptors identified to date on leukocytes, including CX3CR1, all exhibit a 7-transmembrane G protein-linked structure and have been shown to transduce signals leading to cytoskeletal reorganization, integrin activation, and other functions leading to cell migration.10,11 We examined the potential involvement of each of s-FKN-triggered signaling pathways in the s-FKN-enhanced MonoMac6 cells adhesion to fibronectin. Cells were pretreated either with PD98059, a specific MEK inhibitor,30 or with SB202190, a SAPKs inhibitor,31 or with LY294002, a PI3K inhibitor,28 before being tested for their ability to interact with the fibronectin-coated inserts. Our results indicate that s-FKN markedly enhanced adhesion of MonoMac6 cells to fibronectin and that cells remained immobilized even after a lag period of 3 hours, which is compatible with the signaling time course observed for the SAPKs pathways. As shown in Figure 6, enhancement of MonoMac6 cells binding to fibronectin induced by s-FKN was diminished by 58% in the presence of SB202190 (column 2) and by almost 30% with either PD98059 (column 3), LY294002 (column 4), or pertussis toxin (column 5). Interestingly, ablation of the totality of the MAPK activities by the use of SB202190 plus PD98059 led to 85% inhibition of s-FKN-induced adhesion (column 6). Along the same line, consistent with a PI3K-dependent pathway distinct from MAPK cascades, exposure of MonoMac6 cells to a mixture of SB202190 and LY294002 resulted in an 80% inhibition of the chemokine-induced adhesion (column 7). We verified in our migration system that all of these inhibitors have any significant effect on basal MonoMac6 adhesion to fibronectin (data not shown).
s-FKN has been recently reported to exert, in vitro, a chemotactic effect on monocytes, NK cells, and T lymphocytes3,4,8 and to induce the firm adhesion of monocytes and CD8 T lymphocytes.5,14 Although some activation signals triggered in response to other chemokines have been reported,19,32-34 the molecular mechanisms responsible for cell activation by s-FKN remain largely unknown. On the basis of this observation, we became interested in elucidating, in MonoMac6 cells, the effect of s-FKN on the signal transduction pathways induced from its receptor identified as CX3CR1. s-FKN not only stimulated ERK1 and ERK2 in MonoMac6 cell line but also promoted an important increase in SAPKs activities such as JNK1 and p38. Interestingly, the activation kinetic profiles of the different members of the MAPK family fall into 2 categories with a rapid and transient activation of the 2 ERKs activities (within 1 hour), whereas JNK1 and p38 SAPKs exhibited a delayed and sustained time course that persisted for up to 5 hours. These results suggest that complex mechanisms could be triggered in response to s-FKN interaction with its receptor, leading to independent controls of the different MAPKs cascades. s-FKN receptor belongs to a large family of 7 transmembrane-spanning, heterotrimeric GPCRs.10,35 Ligands interacting GPCR have been demonstrated to activate different tyrosine kinases that bridge the G proteins to the ERK pathway.24,36-38 Various nonreceptor tyrosine kinases have recently been shown to participate in myeloid cell signaling responses to growth factors and to IgG binding to Fc receptors, including Lyn, Yes, Hck, Fgr, c-Src,39-43 as well as Syk.44-47 Syk has also been reported to be activated in monocytes stimulated by the engagement of integrins.48-50 Furthermore, this tyrosine kinase has been shown to control JNK activation on CD28-mediated T-cell stimulation.31 To examine the possible involvement of Syk- and Src-like protein tyrosine kinases in s-FKN-induced MAPKs and SAPKs activation, MonoMac6 cells were preincubated in presence of either PP2, a potent inhibitor of the Src kinase family25 or piceatannol, a specific inhibitor of the Syk tyrosine kinase family26 before being exposed to the chemokine. We could demonstrate, in our model, that tyrosine kinases exerted a complex control on the different congeners of the MAPK family, where s-FKN-induced ERKs and p38 activities were respectively abrogated by piceatannol and dramatically attenuated by PP2. This implies that, on s-FKN stimulation, Syk positively controlled the ERKs pathway, whereas c-Src potentiated p38 activation. It is noteworthy that under the same conditions JNK1 activation was insensitive to any of the tyrosine kinase inhibitors. We verified that s-FKN effectively activated both Src and Syk activities following a rapid and sharp profile of stimulation, occurring within minutes, compatible with a subsequent activation of ERKs and p38. Taken collectively, our data lend support to a model where s-FKN activates independently Syk and Src that in turn stimulate, respectively, the ERKs and the p38 pathways, whereas the JNK1 pathway seems to be totally independent of these nonreceptor tyrosine kinases. Chemokines receptors have long been known to be coupled with G proteins sensitive to bacterial toxins.27 Analysis of s-FKN effects on leukocytes has revealed that cell migration responses and calcium mobilization are mediated in a pertussis toxin-dependent manner,8 suggesting a coupling of CX3CR1 to Go/Gi class of G proteins. However, it has recently been demonstrated that the association of chemokines receptors to different G proteins depends on both the receptor and the cell line studied.12,51 To further evaluate the coupling mechanism(s) of the s-FKN receptor and the nature of possible G proteins involved in the signaling events activated in response to this chemokine, MonoMac6 cells were pretreated with pertussis toxin, an inhibitor of Go/i proteins, or cholera toxin, an activator of Gs proteins. Interestingly, we found that ERKs and SAPKs exhibited a differential sensitivity to these toxins. The s-FKN-mediated ERK1, ERK2, and p38 activation was abrogated by the treatment of MonoMac6 cells with both cholera and pertussis toxins, suggesting those pathways are under the coordinated control of Gs and Go/i proteins. JNK1 differed from the other MAPK in the sense that it was insensitive to the action of both kinds of toxin, consistent with the idea that s-FKN up-regulates this cascade through a Gs or Go/i protein-independent pathway. Chemokines have been demonstrated to transmit, via their GPCRs,
intracellular signals resulting in the activation of PI kinases as
evidenced for SDF-1 We found that s-FKN rapidly induced a lipid kinase activity in the MonoMac6 cells. This activity was blocked by a pretreatment of the cells by LY294002 or in presence of detergent added in the kinase assay, pointing to the involvement of a PI3K. However, pretreatment of the cells with LY294002 failed to alter any of the chemokine-mediated MAPKs (ERKs, JNK1, or p38) providing evidence that PI3K activity controls a distinct pathway. To date, scarce information is available on the mechanisms implicated during the diapedesis step in response to s-FKN. This chemokine has been reported to mediate both chemotaxis and adhesion of monocytes,3 but other reports claim that the chemokine-like domain or the entire extracellular domain of s-FKN fail to mobilize human monocytes and THP-1 cells.4 Despite this discrepancy, evidence from many groups likely supports a role of s-FKN in mediating cell adhesion.8,13,14 In this context, we wanted to define which of the s-FKN-activated pathway(s) intervene(s) in its proadhesive properties. Cell adhesion was reduced by 58% with SB202190, a SAPKs inhibitor,31 and by 30%, with either PD98059, a MEK inhibitor,30 or LY294002, a PI3K inhibitor.28 Furthermore, inhibition of all the MAPK cascades (by SB202190 and PD98059) or the concomitant abrogation of SAPK and PI3K (by SB202190 and LY294002) resulted in both cases to more than 80% inhibition of cells adherence, highlighting the concomitant requirement of of SAPKs, ERKs, and PI3K pathways for the mediation of the proadhesive activity of the s-FKN. Finally, the inhibitory effect of pertussis toxin revealed that the strong adhesive effect of s-FKN was also partially dependent on Go/Gi protein activation, in accord with a recent study from Goda et al.14 In conclusion, our data point to a complex coordinated activation of SAPKs, ERKs, and PI3K to efficiently mediate the firm adhesion process engendered by s-FKN in human monocytes.
Submitted May 30, 2000; accepted December 5, 2000.
Supported by the Institut National de la Santè et de la Recherche Mèdicale, the Ligue Nationale Contre le Cancer, Comitè Dèpartemental des Alpes Maritimes (subvention 2000) and the Association pour la Recherche sur le Cancer (grant 5417). B.C. and M.P. contributed equally to this work.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Bernard Rossi, INSERM U364, IFR 50, Facultè de Mèdecine, Avenue de Valombrose, 06107 Nice Cedex 02, France; e-mail: rossi{at}taloa.unice.fr.
1. Baggiolini M, Dewald B, Moser B. Human chemokines: an update. Annu Rev Immunol. 1997;15:675-705[CrossRef][Medline] [Order article via Infotrieve]. 2. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines, CXC and CC chemokines. Adv Immunol. 1994;55:97-179[Medline] [Order article via Infotrieve]. 3. Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640-644[CrossRef][Medline] [Order article via Infotrieve]. 4. Pan YC, Lloyd C, Zhou H, et al. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387:611-617[CrossRef][Medline] [Order article via Infotrieve].
5.
Fong AM, Robinson LA, Steeber DA, et al.
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under flow.
J Exp Med.
1998;188:1413-1419
6.
Muehlhoefer A, Saubermann LJ, Gu X, et al.
Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa.
J Immunol.
2000;164:3368-3376 7. Schwaeble W, Stover C, Schall, et al. Neuronal expression of fractalkine in the presence and absence of inflammation. FEBS Lett. 1998;439:203-207[CrossRef][Medline] [Order article via Infotrieve]. 8. Imai T, Hieshima K, Haskell C, et al. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91:521-530[CrossRef][Medline] [Order article via Infotrieve].
9.
Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM.
Identification of CX3CR1: a chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.
J Biol Chem.
1998;273:23799-23804 10. Murphy PM. The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 1994;12:593-633[CrossRef][Medline] [Order article via Infotrieve]. 11. Premack BA, Schall TJ. Chemokine receptors: gateways to inflammation and infection. Nat Med. 1996;2:1174-1178[CrossRef][Medline] [Order article via Infotrieve].
12.
Arai H, Charo I.
Differential regulation of G-protein-mediated signaling by chemokine receptors.
J Biol Chem.
1996;271:21814-21819
13.
Haskell CA, Cleary MD, Charo IF.
Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction.
J Biol Chem.
1999;274:10053-10058
14.
Goda S, Imai T, Yoshie O, et al.
CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms [In Process Citation].
J Immunol.
2000;164:4313-4320
15.
Myers SJ, Wong LM, Charo IF.
Signal transduction and ligand specificity of the human monocyte chemoattractant protein-1 receptor in transfected embryonic kidney cells.
J Biol Chem.
1995;270:5786-5792
16.
Kuang Y, Wu Y, Jiang H, Wu D.
Selective G protein coupling by C-C chemokine receptors.
J Biol Chem.
1996;271:3975-3978
17.
Bacon KB, Szabo MC, Yssel H, Bolen JB, Schall T.
RANTES induces tyrosine kinase activity of stably complexed p125FAK and ZAP-70 in human T cells.
J Exp Med.
1996;184:873-882
18.
Turner SJ, Domin J, Waterfield MD, Ward SG, Westwick J.
The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/P110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha.
J Biol Chem.
1998;273:25987-25995
19.
Mellado M, Rodriguez-Frade JM, Aragay A, et al.
The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor.
J Immunol.
1998;161:805-813 20. Yen H, Zhang Y, Penfold S, Rollins BJ. MCP-1-mediated chemotaxis requires activation of non-overlappingsignal transduction pathways. J Leuk Biol. 1997;61:529-532[Abstract]. 21. Dubois PM, Palmer D, Webb ML, Ledbetter JA, Shapiro RA. Early signal transduction by the receptor to the chemokine monocyte chemotactic protein-1 in a murine T cell hybrid. J Immunol. 1996;156:1356-1361[Abstract]. 22. Gimbrone MA Jr. Culture of vascular endothelium. Prog Hemost Thromb. 1976;3:1-28[Medline] [Order article via Infotrieve]. 23. Schmid-Antomarchi H, Benkirane M, Breittmayer V, et al. HIV induces activation of phosphatidylinositol 4-kinase and mitogen-activated protein kinase by interacting with T cell CD4 surface molecules. Eur J Immunol. 1996;26:717-720[Medline] [Order article via Infotrieve]. 24. Luttrell LM, Daaka Y, Lefkowitz RJ. Regulation of tyrosine kinase cascades by G-protein-coupled-receptor. Curr Opin Cell Biol. 1999;11:177-183[CrossRef][Medline] [Order article via Infotrieve].
25.
Hanke JH, Gardner JP, Dow LR, et al.
Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor.
J Biol Chem.
1996;271:695-701
26.
Oliver JM, Burg DL, Wilson BS, McLaughlin JL, Geahlen RL.
Inhibition of mast cell Fc 27. Verghese MW, Charles L, Jakoi L, Dillon SB, Snyderman R. Role of a guanine nucleotide regulatory protein in the activation af phospholipase C by different chemoattractants. J Immunol. 1987;138:4374[Abstract].
28.
Baumann P, West SC.
DNA end-joining catalyzed by human cell-free extracts.
Proc Natl Acad Sci U S A.
1998;95:14066-14070 29. Whitman M, Kaplan D, Roberts T, Cantley L. Evidence for two distinct phosphatidylinositol kinases in fibroblasts. Biochem J. 1987;247:165-174[Medline] [Order article via Infotrieve].
30.
Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR.
PD 98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.
J Biol Chem.
1995;270:27489-27494 31. Jacinto E, Werlen G, Karin M. Cooperation between Syk and Rac-1 leads to synergic JNK activation in T lymphocytes. Immunity. 1998;8:31-41[CrossRef][Medline] [Order article via Infotrieve]. 32. Ward SG, Bacon K, Westwick J. Chemokines and T lymphocytes: more than an attraction. Immunity. 1998;9:1-11[CrossRef][Medline] [Order article via Infotrieve]. 33. Ward SG, Westwick J. Chemokines: understanding their role in T-lymphocyte biology. Biochem J. 1998;333:457-470. 34. Sozzani S, Zhou D, Locati M, et al. Receptor and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. J Immunol. 1994;152:3615-3622[Abstract].
35.
Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR.
Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails.
Proc Natl Acad Sci U S A.
1994;91:2752-2756 36. Wan Y, Kurosaki T, Huang X-Y. Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors. Nature. 1996;380:541-544[CrossRef][Medline] [Order article via Infotrieve].
37.
Wan Y, Bence K, Hata A, Kurosaki T, Veillette A, Huang X-Y.
Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling.
J Biol Chem.
1997;272:17209-17215
38.
Luttrel LM, Della Rocca GJ, van Biesen T, Luttrel DK, Lefkowitz RJ.
G 39. Corey S, Eguinoa A, Puyana-Theall K, et al. Granulocyte macrophage-colony stimulating factor stimulates both association and activation of phosphoinositide 3OH-kinase and Src-related tyrosine kinase(s) in human myeloid derived cells. EMBO J. 1993;12:2681-2690[Medline] [Order article via Infotrieve].
40.
Willman CL, Stewart CC, Longacre TL, et al.
Expression of the c-fgr and hck protein-tyrosine kinases in acute myeloid leukemic blasts is associated with early commitment and differentiation events in the monocytic and granulocytic lineages.
Blood.
1991;77:726-734
41.
Zhou M, Lublin DM, Link DC, Brown EJ.
Distinct tyrosine kinase activation and triton X-100 insolubility upon FcgRIIIB ligation in human polymorphonuclear leukocytes.
J Biol Chem.
1995;270:13553-13560
42.
Berton G, Fumagalli L, Laudanna C, Sorio C.
Beta 2 integrin-dependent protein tyrosine phosphorylation and activation of the FGR protein tyrosine kinase in human neutrophils.
J Cell Biol.
1994;126:1111-1121
43.
Gee CE, Griffin J, Sastre L, et al.
Differentiation of myeloid cells is accompanied by increased levels of pp60c-Src protein and kinase activity.
Proc Natl Acad Sci U S A.
1986;83:5131-5135
44.
Agarwal A, Salem P, Robbins KC.
Involvement of p72 Syk, a protein-tyrosine kinase, in Fcg receptor signaling.
J Biol Chem.
1993;268:15900-15905
45.
Hamada F, Aoki M, Akiyama T, Toyoshima K.
Association of immunoglobulin G Fc receptor II with Src-like protein-tyrosine kinase Fgr in neutrophils.
Proc Natl Acad Sci U S A.
1993;90:6305-6309
46.
Durden DL, Liu YB.
Protein-tyrosine kinase p72 Syk in FcgRI receptor signaling.
Blood.
1994;84:2102-2108 47. Ravetch JV. Fc receptors: Rubor redux. Cell. 1994;78:553-560[CrossRef][Medline] [Order article via Infotrieve].
48.
Lin TH, Rosales C, Mondal K, Bolen J, Haskill S, Juliano RL.
Integrin-mediated tyrosine phosphorylation and cytokine message induction in monocytic cells.
J Biol Chem.
1995;270:16189-16197
49.
Miller LA, Hong JJ, Kinch MS, Harrison ML, Geahlen RL.
The engagement of
50.
Gao J, Zoller KE, Ginsberg MH, Brugge JS, Shattil SJ.
Regulation of the pp72syk protein tyrosine kinase by platelet integrin
51.
Amatruda TT, Gerard NP, Gerard C, Simon MI.
Specific interactions of chemoattractant factor receptors with G-proteins.
J Biol Chem.
1993;268:10139-10144
52.
Ganju RK, Brubaker SA, Meyer J, et al.
The a-chemokine, stromal cell-derived factor-1a, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways.
J Biol Chem.
1998;273:23169-23175
53.
al-Aoukaty A, Rolstad B, Maghazachi AA.
Recruitment of pleckstrin and phosphoinositide 3-kinase gamma into the cell membranes, and their association with G beta gamma after activation of NK cells with chemokines.
J Immunol.
1999;162:3249-3255 54. Turner L, Ward SG, Westwick J. A role for phosphoinositide 3-kinase in RANTES induced chemotaxis of T lymphocytes. Biochem Soc Trans. 1995;23:283S[Medline] [Order article via Infotrieve].
55.
Knall C, Worthen GS, Johnson GL.
Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases.
Proc Natl Acad Sci U S A.
1997;94:3052-3057
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  G. E. White, T. C.C. Tan, A. E. John, C. Whatling, W. L. McPheat, and D. R. Greaves Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling Cardiovasc Res, November 12, 2009; (2009) cvp341v2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Gobert, M. van den Eijnden, C. Szyndralewiez, C. Jorand-Lebrun, D. Swinnen, L. Chen, C. Gillieron, F. Pixley, P. Juillard, P. Gerber, et al. GLEPP1/Protein-tyrosine Phosphatase {phi} Inhibitors Block Chemotaxis in Vitro and in Vivo and Improve Murine Ulcerative Colitis J. Biol. Chem., April 24, 2009; 284(17): 11385 - 11395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zhao, A. De, Z. Hu, J. Li, S. M. Mulders, M. D. Sollewijn Gelpke, E.-K. Duan, and A. J. W. Hsueh Gonadotropin Stimulation of Ovarian Fractalkine Expression and Fractalkine Augmentation of Progesterone Biosynthesis by Luteinizing Granulosa Cells Endocrinology, June 1, 2008; 149(6): 2782 - 2789. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Ryu, C.-W. Lee, K.-H. Hong, J.-A. Shin, S.-H. Lim, C.-S. Park, J. Shim, K. B. Nam, K.-J. Choi, Y.-H. Kim, et al. Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia Cardiovasc Res, May 1, 2008; 78(2): 333 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Tchaikovski, G. Fellbrich, and J. Waltenberger The Molecular Basis of VEGFR-1 Signal Transduction Pathways in Primary Human Monocytes Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 322 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lauro, M. Catalano, F. Trettel, F. Mainiero, M. T. Ciotti, F. Eusebi, and C. Limatola The Chemokine CX3CL1 Reduces Migration and Increases Adhesion of Neurons with Mechanisms Dependent on the beta1 Integrin Subunit J. Immunol., December 1, 2006; 177(11): 7599 - 7606. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ancuta, J. Wang, and D. Gabuzda CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J. Leukoc. Biol., November 1, 2006; 80(5): 1156 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Liu, S. Patil, M. Rojas, A. M. Fong, S. S. Smyth, and D. D. Patel CX3CR1 Deficiency Confers Protection From Intimal Hyperplasia After Arterial Injury Arterioscler Thromb Vasc Biol, September 1, 2006; 26(9): 2056 - 2062. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, S. R. Green, F. Almazan, and O. Quehenberger The Amino Terminus and the Third Extracellular Loop of CX3CR1 Contain Determinants Critical for Distinct Receptor Functions Mol. Pharmacol., March 1, 2006; 69(3): 857 - 865. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. N. Davis and J. K. Harrison Proline 326 in the C Terminus of Murine CX3CR1 Prevents G-Protein and Phosphatidylinositol 3-Kinase-Dependent Stimulation of Akt and Extracellular Signal-Regulated Kinase in Chinese Hamster Ovary Cells J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 356 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Gevrey, B. M. Isaac, and D. Cox Syk Is Required for Monocyte/Macrophage Chemotaxis to CX3CL1 (Fractalkine) J. Immunol., September 15, 2005; 175(6): 3737 - 3745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. S. Kim, S. S. Kim, J. J. Cho, D. H. Choi, O. Hwang, D. H. Shin, H. S. Chun, M. F. Beal, and T. H. Joh Matrix Metalloproteinase-3: A Novel Signaling Proteinase from Apoptotic Neuronal Cells That Activates Microglia J. Neurosci., April 6, 2005; 25(14): 3701 - 3711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Daoudi, E. Lavergne, A. Garin, N. Tarantino, P. Debre, F. Pincet, C. Combadiere, and P. Deterre Enhanced Adhesive Capacities of the Naturally Occurring Ile249-Met280 Variant of the Chemokine Receptor CX3CR1 J. Biol. Chem., May 7, 2004; 279(19): 19649 - 19657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vitale, A. Schmid-Alliana, V. Breuil, M. Pomeranz, M.-A. Millet, B. Rossi, and H. Schmid-Antomarchi Soluble Fractalkine Prevents Monocyte Chemoattractant Protein-1-Induced Monocyte Migration via Inhibition of Stress-Activated Protein Kinase 2/p38 and Matrix Metalloproteinase Activities J. Immunol., January 1, 2004; 172(1): 585 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mocsai, H. Zhang, Z. Jakus, J. Kitaura, T. Kawakami, and C. A. Lowell G-protein-coupled receptor signaling in Syk-deficient neutrophils and mast cells Blood, May 15, 2003; 101(10): 4155 - 4163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Vliagoftis Thrombin Induces Mast Cell Adhesion to Fibronectin: Evidence for Involvement of Protease-Activated Receptor-1 J. Immunol., October 15, 2002; 169(8): 4551 - 4558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. M. Morel, C. C. Park, K. Zhu, P. Kumar, J. H. Ruth, and A. E. Koch Signal Transduction Pathways Involved in Rheumatoid Arthritis Synovial Fibroblast Interleukin-18-induced Vascular Cell Adhesion Molecule-1 Expression J. Biol. Chem., September 13, 2002; 277(38): 34679 - 34691. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
-chemokine subclass.
),
32P]ATP (370 MBq/mL, ICN). After incubation at 30°C
for 30 minutes, the reactions were stopped by addition of 9 × Laemmli
sample buffer and boiled for 3 minutes.
counts as described in "Materials and methods."
Data are mean ± SD from triplicates of a single experiment
representative of 3 others.
R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol.
J Biol Chem.
1994;269:29697-29703